Shopping Cart
- Remove All
- Your shopping cart is currently empty
OTS193320, an imidazopyridine compound, acts as an inhibitor of SUV39H2 methyltransferase activity. It effectively reduces global histone H3 lysine 9 tri-methylation levels in breast cancer cells, promoting apoptotic cell death. When combined with Doxorubicin (DOX), OTS193320 enhances the reduction of γ-H2AX levels and decreases cancer cell viability more significantly than when either agent is used alone.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,200 | 7-10 days | |
50 mg | $1,560 | 7-10 days | |
100 mg | $2,370 | 7-10 days |
Description | OTS193320, an imidazopyridine compound, acts as an inhibitor of SUV39H2 methyltransferase activity. It effectively reduces global histone H3 lysine 9 tri-methylation levels in breast cancer cells, promoting apoptotic cell death. When combined with Doxorubicin (DOX), OTS193320 enhances the reduction of γ-H2AX levels and decreases cancer cell viability more significantly than when either agent is used alone. |
Molecular Weight | 536.02 |
Formula | C28H30ClN5O4 |
Cas No. | 2093401-33-1 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.